Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

325
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
325
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

1.6K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.6K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

335
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
335
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

314
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
314
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

3.1K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

356
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
356

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Time to Meaningful Clinical Response Across Approved and Emerging Therapies for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Network Meta-Analysis.

Journal of clinical medicine·2026
Same author

Response to commentary: Aligning dermatology continuing certification and quality outcomes through research.

Journal of the American Academy of Dermatology·2026
Same author

Retirement Patterns in Mohs Micrographic Surgeons and General Dermatologists: A Medicare Part B and Part D Analysis.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]·2026
Same author

Mandatory recertification and practice patterns of dermatologists: A Medicare Part B and Part D Database analysis.

Journal of the American Academy of Dermatology·2026
Same author

Reply to Torres et al, "Reply to Woodie et al, 'Elevated risk of active tuberculosis with interleukin-17, interleukin-23, interleukin-12/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-α inhibitors compared with the general population: A population-based analysis using TriNetX'".

Journal of the American Academy of Dermatology·2026
Same author

Modifiable Factors Such as Nicotine Use, Obesity, Vitamin D Deficiency, Diabetes, and Hypertension Predict Acute Complications of Dermatologic Surgery.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]·2026

Related Experiment Video

Updated: Dec 6, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.5K

Emerging systemic therapies for atopic dermatitis: biologics.

Kelsey B Nusbaum1, Catherine M Nguyen2, Alan B Fleischer2

  • 1University of Cincinnati, College of Medicine, Cincinnati, OH, USA.

The Journal of Dermatological Treatment
|October 13, 2020
PubMed
Summary

Emerging biologic therapies show promise for treating atopic dermatitis (eczema). Emerging biologics like dupilumab, lebrikizumab, and nemolizumab demonstrate efficacy and acceptable safety profiles in clinical trials.

Keywords:
Atopic dermatitisbiologicsmonoclonal antibodiestreatment

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.3K
Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

1.6K

Related Experiment Videos

Last Updated: Dec 6, 2025

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.5K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.3K
Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

1.6K

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Atopic dermatitis treatment options have remained largely static for decades.
  • Recent advancements in understanding atopic dermatitis immunologic pathways have spurred the development of targeted therapies.
  • Biologic agents represent a new frontier in managing this chronic inflammatory skin condition.

Purpose of the Study:

  • To review the efficacy and safety of emerging biologic therapies for atopic dermatitis.
  • To analyze data from phase 2 and 3 clinical trials of targeted biologic agents.
  • To provide an overview of the current landscape of biologic treatments for atopic dermatitis.

Main Methods:

  • Systematic literature review of randomized, placebo-controlled trials.
  • Focused on monoclonal antibody therapies for atopic dermatitis.
  • Literature search conducted up to March 1, 2020.

Main Results:

  • Targeted biologic therapies demonstrate acceptable safety profiles.
  • Dupilumab, lebrikizumab, and nemolizumab show significant efficacy in improving clinical severity of atopic dermatitis.
  • These agents effectively reduce pruritus (itching) associated with the condition.

Conclusions:

  • The expanding class of biologic drugs offers hope for patients with treatment-resistant atopic dermatitis.
  • Standardized core measurements are essential for future trials to compare biologic agents effectively.
  • Continued research and validated outcome measures will advance evidence-based medicine in atopic dermatitis treatment.